Today: 1 May 2026
XRP price today: Ripple’s UK FCA approvals put the $2 level back in focus
9 January 2026
1 min read

XRP price today: Ripple’s UK FCA approvals put the $2 level back in focus

New York, Jan 9, 2026, 10:14 ET — Regular session

  • XRP edged down roughly 0.5%, hovering around $2.09 late in the morning session.
  • Ripple secured fresh UK clearances as the company ramps up its push into regulated payments.
  • All eyes now turn to next week’s U.S. inflation numbers, as traders hunt for fresh signals on rate direction.

XRP slipped about 0.5% Friday, trading at $2.09, even after Ripple secured fresh regulatory approvals in the UK. The token hovered just shy of $2, holding steady despite the news.

UK permissions matter—a lot—since regulation is still the main force dictating whether crypto firms can target large institutions, and whether banks will even approach token rails. Ripple is banking on licensing, aiming to reshape its payments unit into something closer to backbone infrastructure, moving away from its image as just another crypto bet.

XRP’s been acting like a high-beta risk asset lately, tracking along with shifting crypto moods and U.S. rate outlooks. So when macro data and liquidity are in play, it complicates how investors price any “good news.”

Ripple has landed both an Electronic Money Institution license and a Cryptoasset Registration from the UK’s Financial Conduct Authority, clearing the way to expand its licensed payments platform for local institutions. “Finance is undergoing a fundamental shift,” Ripple President Monica Long said in a statement.

Cassie Craddock, managing director for Ripple in the UK and Europe, described the FCA green light as “a pivotal moment.” She said regulatory clarity could accelerate adoption.

The FCA’s go-ahead isn’t a free pass. According to Finance Magnates, Ripple Markets UK remains subject to restrictions and will require additional sign-off before it can expand specific crypto operations or target some retail customers.

Elsewhere, bitcoin hovered near $90,884, barely budging, with ether sliding 1.1% to $3,388. XRP didn’t get any help from the quiet market backdrop.

Right now, traders continue to view the early January action as a consolidation stretch. Itai Smidt at Investing.com pointed out support sitting at $2.15-$2.10, and down to $2.07-$2.00, while notable resistance appears close to $2.22 and $2.26.

Even so, it’s hard to ignore the risks. In a fresh filing, the WisdomTree XRP Fund moved to pull its registration — a sharp signal that crypto products aren’t immune to setbacks. Market flows, after all, can reverse fast if sentiment shifts to risk-off.

Traders are eyeing the December U.S. consumer price index, out Jan. 13 at 8:30 a.m. ET, before turning attention to the Federal Reserve’s Jan. 27-28 policy meeting for rate signals.

Stock Market Today

  • Lake Shore Bancorp (LSBK) Ex-Dividend Date Set for May 4, 2026
    May 1, 2026, 11:24 AM EDT. Lake Shore Bancorp Inc (LSBK) will go ex-dividend on May 4, 2026. The quarterly dividend is $0.09 per share, about 0.57% of its recent $15.92 stock price. This means shares may open roughly 0.57% lower on that date, all else equal. The dividend pays out on May 13, 2026, and the company's current annualized dividend yield is approximately 2.26%. LSBK shares have traded between $11.50 and $16.28 over the past 52 weeks, with the latest close near the high at $15.92. Investors track such metrics to gauge dividend sustainability and stock performance. On Friday, shares edged up 0.2%.

Latest article

Cue Biopharma Stock Nearly Doubles After Allergy Drug Deal, New CEO and $30 Million Raise

Cue Biopharma Stock Nearly Doubles After Allergy Drug Deal, New CEO and $30 Million Raise

1 May 2026
BOSTON, May 1, 2026, 11:03 (EDT) Cue Biopharma shares jumped in Friday morning trading after the Boston biotechnology firm announced a new allergy drug license, a $30 million private placement and the appointment of Shao-Lee Lin as chief executive. The shares were up 91.4% at $28.21 at 11:03 a.m. EDT, with Nasdaq trading open, after closing Thursday at $14.74, market data showed. The stock had opened as high as $33.75 before paring gains. The move matters now because Cue is trying to reset its business around clinical-stage immunology assets after a turbulent period for the stock. Last week it implemented
Atlassian Corporation Stock Jumps 22% as AI-Led Earnings Beat Tests SaaS Selloff

Atlassian Corporation Stock Jumps 22% as AI-Led Earnings Beat Tests SaaS Selloff

1 May 2026
Atlassian shares surged 22% Friday after the company beat quarterly estimates and raised its annual revenue forecast. Fiscal Q3 revenue climbed 32% to $1.787 billion, but Atlassian posted a $98.4 million net loss after restructuring charges. Cloud revenue rose 29% as customers expanded Jira use and adopted more AI features. Remaining performance obligations jumped 37% to $4.0 billion.
Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play
Previous Story

Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

Netflix stock slides below $90 as Goldman trims target and Warner bid fight drags on
Next Story

Netflix stock slides below $90 as Goldman trims target and Warner bid fight drags on

Go toTop